| 前收市價 | 17.13 |
| 開市 | 17.50 |
| 買盤 | 13.54 x 100 |
| 賣出價 | 17.87 x 100 |
| 今日波幅 | 15.43 - 17.50 |
| 52 週波幅 | 15.43 - 33.99 |
| 成交量 | |
| 平均成交量 | 1,846,154 |
| 市值 | 2.556B |
| Beta 值 (5 年，每月) | 無 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -0.37 |
| 業績公佈日 | 2024年7月31日 - 2024年8月05日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 28.68 |
ZacksAcadia Pharmaceuticals (ACAD) Tops Q1 Earnings Estimates
Acadia (ACAD) delivered earnings and revenue surprises of 150% and 0.52%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
ZacksWatch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?
Let us look at five drug, generic companies, PRGO, IOVA, VTRS, TEVA and ACAD, which are gearing up for their earnings release this week.
InvestorPlace3 Pharma Stocks to Sell in April Before They Crash & Burn
There are some pharma stocks to sell in April. Holding these companies is too risky, especially as the industry faces increasing regulatory scrutiny and pricing pressures. Several major pharmaceutical firms are grappling with patent cliffs, where key drug exclusivities are expiring. This opens the door for generic competition. Moreover, with the broader market presenting attractive investment options, holding on to these riskier pharma plays could result in significant opportunity cost. Many pro
